Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04857684
Recruitment Status : Not yet recruiting
First Posted : April 23, 2021
Last Update Posted : April 23, 2021
Genentech, Inc.
Information provided by (Responsible Party):
Joseph Franses, MD, PHD, Massachusetts General Hospital

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : December 1, 2025